A Study of Centanafadine in Pediatrics with Attention Deficit Hyperactivity Disorder

  • Ages 4-5
  • Diagnosis of or symptoms consistent with ADHD
  • Able to swallow a capsule
  • Has not benefited from therapeutic intervention, or symptoms are severe enough to warrant medication intervention
  • If you have history of medical issues such as seizures, blood disorders, or other major health conditions you may not qualify for this trial
  • Open-label study to follow
  • Method of Administration: Oral / Capsule
    • Length/Duration: 7 Weekly Visits
    • Location: 721 North Magnolia Avenue, Orlando FL 32803
    • Compensation: $125 / visit
    • Participants may:
      • See a doctor or medical staff at no cost
      • Have access to trial medications
      • Receive compensation for time and travel
  • This field is for validation purposes and should be left unchanged.